Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:biotechnology
|
| gptkbp:acquired_by |
gptkb:Sarepta_Therapeutics
|
| gptkbp:clinical_trial |
gptkb:Duchenne_muscular_dystrophy
|
| gptkbp:collaboration |
academic institutions
|
| gptkbp:focus |
gptkb:gene_therapy
|
| gptkbp:founded |
gptkb:2017
|
| gptkbp:founder |
Dr. Chris Garabedian
|
| gptkbp:headquarters |
gptkb:Cincinnati,_Ohio
|
| https://www.w3.org/2000/01/rdf-schema#label |
Myonexus Therapeutics
|
| gptkbp:investment |
gptkb:venture_capital
|
| gptkbp:leadership |
Dr. Chris Garabedian
|
| gptkbp:partnership |
gptkb:Sarepta_Therapeutics
|
| gptkbp:product |
MYO-102
MYO-103 MYO-101 |
| gptkbp:regulatory_compliance |
gptkb:FDA
|
| gptkbp:research |
gptkb:muscular_dystrophy
|
| gptkbp:research_focus |
rare diseases
|
| gptkbp:targets |
muscle diseases
|
| gptkbp:technology |
AAV gene delivery system
|
| gptkbp:website |
myonexus.com
|
| gptkbp:bfsParent |
gptkb:Sarepta_Therapeutics
|
| gptkbp:bfsLayer |
5
|